A 12-week, Phase II, multi-center, randomized, double-blind, placebo-controlled study to assess the response to treatment (American College of Rheumatology 20 percent response criteria) and to determine a biomarker profile in adult patients with established rheumatoid arthritis responding to ACZ885 [canakinumab] (anti interleukin 1beta monoclonal antibody) as compared to healthy subjects exposed to ACZ885.

Trial Profile

A 12-week, Phase II, multi-center, randomized, double-blind, placebo-controlled study to assess the response to treatment (American College of Rheumatology 20 percent response criteria) and to determine a biomarker profile in adult patients with established rheumatoid arthritis responding to ACZ885 [canakinumab] (anti interleukin 1beta monoclonal antibody) as compared to healthy subjects exposed to ACZ885.

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Feb 2015

At a glance

  • Drugs Canakinumab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Biomarker; Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 02 Sep 2010 Actual end date (Sep 2008) added as reported by ClinicalTrials.gov.
    • 27 Aug 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top